Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia.

This article explores the role of TP53 expression in chronic myelomonocytic leukemia (CMML) and its implications for prognosis and treatment. TP53 is a gene commonly mutated in cancer, but CMML patients have low rates of TP53 mutations. The study found that low TP53 expression in CMML patients was linked to worse outcomes and reduced response to treatment. The findings suggest that altered TP53 expression could serve as a marker for poor prognosis and resistance to therapy in CMML. The study also highlights potential therapeutic strategies targeting TP53 expression in CMML patients. [Extracted from the article]